Comparison of Friedewald, Martin/Hopkins, and Sampson formulae with direct LDL measurement in hyperlipidaemic and normolipidaemic adults
Comparison of Friedewald, Martin/Hopkins, and Sampson formulae with direct LDL measurement
Abstract
ABSTRACT
Objective: In our study, we aimed to compare and validate the performance of the Friedewald, Martin/Hopkins, and Sampson formulae with direct LDL-C measurement.
Material and Methods: The study was a retrospective investigation which by the Department of Medical Biochemistry of the Ankara Training and Research Hospital between 1 January 2021 and 31 December 2022. Our study evaluated the results of 6297 patients aged 18-99 years who underwent cholesterol panel TC, TG, HDL-C and direct LDL-C in our laboratory. Estimated LDL-C calculated according to Friedewald, Martin/Hopkins, and Sampson formulae.
Results: All three formulae showed a stronger positive correlation with d-LDL-C (0.905, 0.897, and 0.886, respectively, for all data, p<0.001). In addition, when we compared the total median difference (1st-3rd quartile) of all formulae, it was it was -0.69 (-1.62-0.39) for Friedewald, 0.034 (-0.74 -1.14) for Martin/Hopkins and -0.40 (-1.19-0.55) for Sampson. According to Passing Bablok regression analyses, the intercept was determined as -0.97 (95% CI = -1.01 to -0.93), 0.41 (95%=0.37 to 0.44) and -0.05 (-0.08 to -0. 03) and slopes were calculated as 1.083 (95% CI = 1.07-1.09), 0.88 (0.88 to 0.89) and 0. 90 (95% = 0.89 to 0.90) for Friedewald, Martin/Hopkins and Sampson, respectively.
Conclusions: Our findings suggest that Martin/Hopkins formula indicated a better performance than Friedewald and Sampson formulae. We figured out utilizing the Martin/Hopkins formula as a good alternative for estimated LDL-C in Turkish adults.
References
References
1. World Health Organisation. Cardiovascular diseases (CVDs), 2021. Available: https:// www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
2. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 Oct 14; 37(39):2999-3058. doi: 10.1093/eurheartj/ehw272.
3. Li J, Xin Y, Li J, Meng M, Zhou L, Qiu H, et al. Evaluation of Sampson equation for LDL-C in acute coronary syndrome patients: a Chinese population-based cohort study. Lipids Health Dis. 2022; 21(1):39. doi: 10.1186/s12944-022-01648-4.
4. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS and Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013; 310:2061–8.
5. Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A new equationfovrcalculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020; 5:540–548.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
7. Azimi V, Farnsworth CW, Roper SM. Comparison of the Friedewald equation with Martin and Sampson equations for estimating LDL cholesterol in hypertriglyceridemic adults. Clin Biochem. 2022; 108:1-4. doi: 10.1016/j.clinbiochem.2022.07.005.
8. Ephraim, R.K.D., Ativi, E., Ashie, S.A. et al. Assessment of estimated low-density lipoprotein-cholesterol (LDL-c) equations: a systematic review and meta-analysis. Bull Natl Res Cent 2023;47: 71. https://doi.org/10.1186/s42269-023-01046-5
9. Rim JH, Lee YH, Lee MH, Kim HY, Choi J, Lee BW, et al. Comparison and validation of 10 equations including a novel method for estimation of LDL-cholesterol in a 168,212 Asian population. Medicine 2016;95(14):1–8
10. Kang M, Kim J, Lee SY, Kim K, Yoon J, Ki H. Martin's Equation as the Most Suitable Method for Estimation of Low-Density Lipoprotein Cholesterol Levels in Korean Adults. Korean J Fam Med. 2017;38(5):263-269. doi: 10.4082/kjfm.2017.38.5.263.
11. Piani F, Cicero AFG, Ventura F, Dormi A, Fogacci F, Patrono D, et al. BLIP Study Group. Evaluation of twelve formulas for LDL-C estimation in a large, blinded, random Italian population. Int J Cardiol 2021; 330:221-227. doi: 10.1016/j.ijcard.2021.02.009.
12. Martínez-Morillo E, García-García M, Concha MAL, Varas LR. Evaluation of a new equation for estimating low-density lipoprotein cholesterol through the comparison with various recommended methods. Biochem Med (Zagreb). 2021;31(1):010701. doi: 10.11613/BM.2021.010701.
13. Ertürk Zararsız G, Bolat S, Cephe A, Kochan N, Yerlita SI, Doğan HO, et al. Validation of Friedewald, MartinHopkins and Sampson Low-Density Lipoprotein Cholesterol Equations. PLoS ONE 2022, 17, e0263860.
14. Khan M, Ain QT, Nawaz A, Iqbal Khan M, Sadiq F. Indirect calculation of LDL using thirteen equations in Pakistani population. Clin Chim Acta. 2022; 536:77-85.
15. Steyn N, Muller Rossouw H, Pillay TS, Martins J. Comparability of calculated LDL-C with directly measured LDL-C in selected paediatric and adult cohorts. Clin Chim Acta. 2022; 537:158-166.
16. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 ;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002.
1 17. Mach F, Baigent C, Catapano AL, Koskinas CK, Casula M, Badimon L, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
Copyright (c) 2024 Medine ALPDEMİR
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.